ROSEN Law Firm Urges DermTech, Inc. Investors to Act Ahead of Important Deadline in Securities Class Action

The respected global investor rights law firm, ROSEN, has issued an essential reminder to investors who acquired DermTech, Inc. DMTK securities between May 3, 2022, and November 3, 2022. The notification concerns a pivotal December 15, 2023, lead plaintiff deadline in a securities class action suit.

Understanding the Class Action

Investors who have purchased securities of DermTech, Inc. DMTK during the defined Class Period may be eligible for restitution without incurring out-of-pocket fees, based on a contingency fee arrangement. A previously initiated class action demands that those wishing to serve as lead plaintiff file a motion with the Court by no later than December 15, 2023. The role of the lead plaintiff is to represent other members of the class in the proceedings.

The Allegations Against DermTech

The lawsuit alleges that, throughout the Class Period, defendants made materially false and misleading statements, and failed to disclose significant adverse details about the business operations, and prospects of DermTech, Inc. DMTK. The company reportedly faced challenges with collections from commercial payers, which led to a lower average selling price for their DermTech Melanoma Test (DMT). Consequently, revenue growth was expected to suffer, a fact not disclosed to investors. Once the market became aware of these challenges, the claim asserts that investors bore financial damages.

Legal Support for Investors

ROSEN Law Firm is renowned for representing global investors, specializing in securities class actions and shareholder derivative litigation. With a history of substantial settlements and a reputation for thorough litigation, ROSEN emphasizes the importance of selecting qualified counsel proficient in managing leadership roles in class actions. The firm boasts many successes, including record settlements and a consistently high ranking in securities class action settlements. The ongoing litigation offers investors the option to join the class action or seek more information on the case.

Next Steps for Affected Investors

Investors who believe that they have been affected by the alleged misconduct are encouraged to join the class action or to reach out to ROSEN's legal team for further information. Legal representation at this stage is crucial for ensuring that affected shareholders are adequately represented and that their interests are advocated throughout the legal proceedings.

DermTech, Inc. at a Glance

DermTech, Inc. DMTK, a molecular diagnostics company, operates out of La Jolla, California. It focuses on developing and marketing innovative non-invasive genomic tests for the diagnosis of skin cancer, inflammatory diseases, and age-related conditions within the United States.

ROSEN, DermTech, Investors, Deadline, Securities, ClassAction, LeadPlaintiff